Sarepta CEO has big ambition for muscular dystrophy gene therapy

Sarepta Therapeutics CEO Doug Ingram told CNBC on Friday he has a “big ambition” to get the company’s Duchenne muscular dystrophy gene therapy to patients as quickly as possible.

Source link

Leave a Comment

Two health scares at U.S. airports tied to Mecca pilgrims: U.S. officialsSepsis survivor calls for 'life-saving' machines for Wales